

S/N 09/204,427

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	HADDADA ET AL.	Examiner:	M. WILSON
Serial No.:	09/204,427	Group Art Unit:	1632
Filed:	DECEMBER 3, 1998	Docket No.:	8076.102USC1
Confirmation No.:	5504	Customer No.:	23552
Title:	DEFECTIVE RECOMBINANT ADENOVIRUSES EXPRESSING CYTOKINES FOR ANTITUMOR TREATMENT		

CERTIFICATE UNDER 37 CFR 1.6(d):

I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office on April 5, 2004.

By: 
Name: Sheryl A. BoerboomINFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b))

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted before the mailing of a first Office Action after the filing of a Request for Continued Examination under 37 C.F.R. § 1.114 or a CPA under 37 C.F.R. § 1.53(d). Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449. Applicants received a Notice of Allowance in this case, but subsequently, became aware of the following documents.

In accordance with 37 C.F.R. § 1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.


Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300

Date: April 5, 2004

Katherine M. Kowalchuk
Katherine M. Kowalchuk
Reg. No. 36,848
KMK:sab



Date Mailed: APRIL 5, 2004

Sheet 1 of 1

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 8076.10ZUSC1	Application Number: 09/204,427
	Applicant: HADDADA ET AL	
	Filing Date: DECEMBER 3, 1998	Group Art Unit: 1632

RECEIVED

APR 06 2004

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Addison, C. et al., "Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model", <u>Proc. Natl. Acad. Sci. USA</u> , 92:8522-8526 (Aug. 1995)
	Schmidt-Wolf, G. et al., "Cytokines and clinical gene therapy", <u>Eur. J. Immunol.</u> , 25:1137-1140 (1995)
	Clark, I. et al., "Roles of TNF in malaria and other parasitic infections", <u>Immunology Series</u> , 56:365-407 (1992) Medline Accession No. 92199019 (Abstract only)
	Ovington, K. et al., "Cytokines and immunological control of <i>Elmeria</i> spp.", <u>International Journal for Parasitology</u> , 25(11):1331-51 (Nov. 1995) Medline Accession No. 96229273 (Abstract only)
	Brunda, M. J., "Interleukin-12", <u>Journal of Leukocyte Biology</u> , 56(2):280-288 (Feb. 1994) Medline Accession No. 94132739 (Abstract only)
	Utsunomiya, T. et al., "A relationship between the generation of burn-associated type 2 T cells and their antagonistic cells in thermally injured mice", <u>Burns</u> , 23(4):281-287 (June 1997) Medline Accession No. 97391891 (Abstract only)

23552

PATENT TRADEMARK OFFICE

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE